Immediate and delayed autologous abdominal microvascular flap breast reconstruction in patients receiving adjuvant, neoadjuvant or no radiotherapy: a meta-analysis of clinical and quality-of-life outcomes by Khajuria, A et al.
                          Khajuria, A., Charles, W. N., Prokopenko, M., Beswick, A., Pusic, A. L.,
Mosahebi, A., ... Winters, Z. E. (2020). Immediate and delayed autologous
abdominal microvascular flap breast reconstruction in patients receiving
adjuvant, neoadjuvant or no radiotherapy: a meta-analysis of clinical and
quality-of-life outcomes. BJS Open, 4(2), 182-196.
https://doi.org/10.1002/bjs5.50245
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1002/bjs5.50245
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Wiley at
https://bjssjournals.onlinelibrary.wiley.com/doi/full/10.1002/bjs5.50245 . Please refer to any applicable terms of
use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
Systematic review
Immediate and delayed autologous abdominal microvascular
flap breast reconstruction in patients receiving adjuvant,
neoadjuvant or no radiotherapy: a meta-analysis of clinical
and quality-of-life outcomes
A. Khajuria1,3 , W. N. Charles3, M. Prokopenko4, A. Beswick6, A. L. Pusic7, A. Mosahebi4,
D. J. Dodwell2 and Z. E. Winters5
1Kellogg College, Nuffield Department of Surgery, and 2Nuffield Department of Population Health, University of Oxford, Oxford, 3Department of
Surgery and Cancer, Imperial College London, 4Department of Plastic Surgery, Royal Free Hospital, 5Surgical Intervention Trials Unit, Division of
Surgery and Interventional Science, University College London, London, and 6School of Clinical Sciences, University of Bristol, Bristol, UK, and
7Patient-Reported Outcomes, Value and Experience Centre, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
Correspondence to:Mr A. Khajuria, Department of Surgery and Cancer, Imperial College London, Praed Street, London W21NY, UK (e-mail:
ak8609@imperial.ac.uk)
Background: Effects of postmastectomy radiotherapy (PMRT) on autologous breast reconstruction
(BRR) are controversial regarding surgical complications, cosmetic appearance and quality of life (QOL).
This systematic review evaluated these outcomes after abdominal free flap reconstruction in patients
undergoing postoperative adjuvant radiotherapy (PMRT), preoperative radiotherapy (neoadjuvant radio-
therapy) and no radiotherapy, aiming to establish evidence-based optimal timings for radiotherapy and
BRR to guide contemporary management.
Methods: The study was registered on PROSPERO (CRD42017077945). Embase, MEDLINE, Google
Scholar, CENTRAL, ScienceCitation Index andClinicalTrials.govwere searched (January 2000 to August
2018). Study quality and risk of bias were assessed using GRADE and Cochrane’s ROBINS-I respectively.
Results: Some 12 studies were identified, involving 1756 patients (350 PMRT, 683 no radiotherapy and
723 neoadjuvant radiotherapy), with a mean follow-up of 27⋅1 (range 12⋅0–54⋅0)months for those having
PMRT, 16⋅8 (1⋅0–50⋅3)months for neoadjuvant radiotherapy, and 18⋅3 (1⋅0–48⋅7)months for no radio-
therapy. Three prospective and nine retrospective cohorts were included. There were no randomized
studies. Five comparative radiotherapy studies evaluated PMRT and four assessed neoadjuvant radio-
therapy. Studies were of low quality, with moderate to serious risk of bias. Severe complications were
similar between the groups: PMRT versus no radiotherapy (92 versus 141 patients respectively; odds ratio
(OR) 2⋅35, 95 per cent c.i. 0⋅63 to 8⋅81, P= 0⋅200); neoadjuvant radiotherapy versus no radiotherapy (180
versus 392 patients; OR 1⋅24, 0⋅76 to 2⋅04, P=0⋅390); and combined PMRT plus neoadjuvant radiother-
apy versus no radiotherapy (272 versus 453 patients; OR 1⋅38, 0⋅83 to 2⋅32, P=0⋅220). QOL and cosmetic
studies used inconsistent methodologies.
Conclusion: Evidence is conflicting and study quality was poor, limiting recommendations for the timing
of autologous BRR and radiotherapy. The impact of PMRT and neoadjuvant radiotherapy appeared to be
similar.
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Introduction
Breast cancer is the commonest malignancy and lead-
ing cause of cancer-related mortality in women1,2.
Breast-conserving surgery (BCS) with radiotherapy or
mastectomy are recommended treatments, with compara-
ble oncological outcomes3,4. Autologous abdominal-based
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free flap and implant-based procedures are the approaches
used most frequently in immediate breast reconstruction
(BRR)5. Autologous BRR has the inherent advantage of
using the patient’s own tissues, taken from a different part
of the body where there is excess fat and skin, to restore
breast volume and appearance after mastectomy. Various
donor sites can be used, most commonly the abdomen6.
Adjuvant locoregional postmastectomy radiotherapy
(PMRT) of the chest wall, and potentially of the regional
lymph nodes, has been indicated historically for locally
advanced disease7,8. These indications increased following
the Early Breast Cancer Trialists’ Collaborative Group9
meta-analyses, which showed significantly improved
disease-free and overall survival after PMRT and regional
node irradiation in women at intermediate risk (tumour
size 50mm or less and 1–3 positive lymph nodes)10. Newly
proposed US guidelines11 emphasize the need to consider
the lower recurrence rates associated with contemporary
practice and the benefits of systemic therapy12. Current
recommendations for PMRT in the intermediate-risk
group remain controversial, pending the results of the
SUPREMO (Selective Use of Postoperative Radiotherapy
aftEr MastectOmy) trial, evaluating chest wall and/or
axillary radiotherapy13,14.
Adjuvant radiotherapy (PMRT) may have deleterious
effects on breast cosmetic outcomes, quality of life (QOL)
and surgical complications after immediate BRR15. Pre-
vious studies evaluating the impact of PMRT on types
of immediate BRR showed its potential feasibility in this
setting, with lower morbidity rates compared with those
of implant-based procedures5,16–18. Surprisingly, the rapid
adoption of immediate implant-based reconstruction in
about 70 per cent of women, compared with 34 per cent of
autologous procedures when PMRT is recommended, may
be influenced by surgeon and patient preferences, regard-
less of current evidence15,17,19.
Increasing recommendations for PMRT and immediate
BRR have prompted a need to consider their optimal
sequence. Previous systematic reviews have not provided
clarity concerning the choice between immediate and
delayed BRR9. Despite this, immediate autologous BRR
is commonly recommended in the setting of PMRT,
given the potential long-term benefits on patients’ QOL
and breast cosmetic satisfaction20,21. Currently, imme-
diate autologous BRR and PMRT recommendations
are variable22,23. A systematic review24 in 2011 showed
methodological variations in the definitions of surgical
complications, precluding interstudy comparisons.
Complications of autologous breast reconstruction with
PMRT include: poor wound-healing, flap-related fat
necrosis, fibrosis and contracture, which reduce breast
volume5. Surgical complications contribute variably to
decreased patient satisfaction and impaired cosmetic
outcomes5. A standardized core set of outcomes for BRR
has been proposed25 involving a range of complications,
including flap-related complications and the need for
further unplanned surgery. The BRR core outcome set
has yet to recommend a standardized measurement tool
for evaluating surgical complications. Most surgeons
use the Clavien–Dindo classification (CDC)26. Patient-
reported QOL outcomes using validated BRR question-
naires, such as the BREAST-Q and the European
Organisation for Research and Treatment of Cancer
(EORTC) Quality-of-Life Questionnaire (QLQ)-
BRECON23, are recommended to evaluate comparative
effectiveness20,27–32.
This systematic review aimed to evaluate the quality
and strengths of the current evidence regarding surgical
complications in autologous abdominal flaps in the con-
text of the receipt and timing of radiotherapy related to
PMRT5,6 and, less commonly, neoadjuvant radiotherapy,
generally administered before skin-sparing mastectomy
and immediate breast reconstruction33, including assess-
ment of QOL34.
Methods
The protocol was registered and published on the
Prospective Register of Systematic Reviews PROS-
PERO (CRD42017077945)35. The authors adhered to the
PRISMA statement36.
Search strategies
A comprehensive search of the MEDLINE (Ovid SP),
Embase (Ovid SP), Google Scholar, Cochrane Controlled
Register of Trials (CENTRAL), Science citation index
databases and ClinicalTrials.gov (January 2000 to August
2018) was conducted, identifying the relevant studies.
Combinations of Medical Subject Headings (MeSH) terms
and free text were used, including Boolean logical opera-
tors for the search strategy. References of included articles
were also screened for their relevance. The example of an
Embase (Ovid SP) search strategy was adopted for other
databases (Appendix S1, supporting information).
Identification and selection of studies
Database-related searches were entered into an
EndNote™ X8 library (Clarivate Analytics, Philadel-
phia, Pennsylvania, USA). Study screening was performed
independently in two stages by two investigators using
prespecified screening criteria.
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In stage 1, two authors independently screened titles and
abstracts. Discrepancies were resolved by consensus with
the senior author. Remaining doubts regarding an article
resulted in a review of the complete publication.
In stage 2, full-text studies from stage 1 were screened
independently for their eligibility by two reviewers.
Discrepancies were resolved by consensus with a third
reviewer. Authors of eligible studies were contacted (via
e-mail) to reconcile any methodological issues or to pro-
vide more detailed information on data for individual types
of autologous flap.
Study design
All primary human studies evaluating surgical complica-
tions for autologous free flap (microvascular) abdominal
BRR in breast cancer and types of radiotherapy (PMRT,
neoadjuvant and no radiotherapy) were included. Out-
comes also included patient-reported QOL and cosmetic
assessments. Radiotherapy groups were compared with a
control or no radiotherapy group in comparative studies,
compatible with immediate and delayed BRR. Commonly
performed autologous abdominal flaps included: deep infe-
rior epigastric perforator (DIEP), transverse rectus abdo-
minis myocutaneous (TRAM) and the superficial inferior
epigastric artery perforator (SIEA)6.
Inclusion criteria
Inclusion criteria were: women aged at least 18 years with
a diagnosis of invasive breast cancer (TNM categories:
T0–3, N1–3, Mx, M0), undergoing immediate or delayed
abdominal autologous BRR using free flaps (DIEP, TRAM
or SIEA) who received adjuvant radiotherapy (PMRT),
neoadjuvant radiotherapy or no radiotherapy.
Clinical studies that involved at least 50 patients were
included (RCTs, prospective and retrospective comparative
observational studies, and case series).
Exclusion criteria
Review articles, conference abstracts, simulation stud-
ies and clinical studies in non-human subjects were
not included, along with studies involving patients who
received segmental or partial mastectomy, technical
descriptions of operative repair with no outcome mea-
sures, BRR unrelated to breast cancer, implant-based
reconstructions and other non-abdominal autologous flaps.
Risk of bias and quality of studies
Cochrane’s ROBINS-I (Risk Of Bias In Non-randomised
Studies – of Interventions) tool was used for comparative
studies37. This comprises seven domains from which the
risk of bias may be ascertained to produce an overall
risk-of-bias score37. The Grading of Recommendations,
Assessment, Development, and Evaluations (GRADE)
tool38 was used to evaluate the methodological quality of
individual studies.
Study outcomes
Primary outcomes were surgical complications includ-
ing: Clavien–Dindo classification (CDC) grades II and
III26; partial flap loss; total flap loss; fat necrosis (CDC
grades, when reported)39; number(s) of unplanned reop-
erations for surgical complications (excluding cosmetic
revisions); and number(s) of total complications. A surgical
complication was defined as an adverse, postoperative,
surgery-related event that required additional treatment16.
If CDC grades were not defined, the complications
reported by the included studies were graded retrospec-
tively according to the CDC by two independent authors;
any discrepancy was discussed and agreed with the senior
author.
Secondary outcomes were assessed using patient-
reportedQOL-validated questionnaires (COnsensus-based
Standards for the Selection of health Measurement
INstruments (COSMIN)40,41, Breast Questionnaire
(BREAST-Q), the EORTC Quality-of-Life Question-
naire (QLQ) – Breast Cancer 2342, the Quality-of-Life
Cancer Generic Questionnaire (QLQ-C30)43, theNumer-
ical Pain Rating Scale (NPRS)44,45, the Patient-Reported
Outcomes Measurement Information System – Profile 29
(PROMIS-29)46, theMcGill PainQuestionnaire (MPQ)47,
the Generalized Anxiety Disorder Scale (GAD-7)48 and
the Patient Health Questionnaire (PHQ-9)49), as well as
assessment of cosmetic outcomes using independent panel
or self assessments of medical photographs, and surface
imaging using the Vectra®XT three-dimensional system50
(Canfield Scientific, Parsippany, New Jersey, USA).
Data extraction, collection and management
Two authors independently extracted data from full-text
articles using a standard data form. Any discrepancies were
resolved by consensus with a third reviewer. Reporting
authors of original articles were contacted on up to two
occasions relating to missing data or where additional
information was required.
Data extraction included: first author, year of publication,
study design, study setting, number of centres, duration of
follow-up, study population and participant demographics
(mean age, BMI, smoking, co-morbidities).
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Fig. 1 PRISMA diagram for the review
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RT, radiotherapy; BRR, breast reconstruction.
Surgical complications were recorded using CDC:
grades II–III26. Two authors reviewed eligible studies and
classified each complication according to the CDC26 if
unreported.
QOL and cosmetic outcomes were listed.
Statistical analysis
When two or more studies reported outcome data, these
were pooled using Review Manager 5.3 software (The
Cochrane Collaboration, The Nordic Cochrane Centre,
Copenhagen, Denmark). Odds ratios with 95 per cent con-
fidence intervals were used to evaluate dichotomous out-
comes (surgical complications). Standard mean differences
(with 95 per cent c.i.) were used for continuous outcomes
between treatment groups. Rates of each complication (fat
necrosis, partial and total flap loss, infection and wound
complications (dehiscence and delayed wound healing))
were compared for PMRT (versus no radiotherapy) and
neoadjuvant radiotherapy (versus no radiotherapy). Data
were also pooled to provide an overall summary measure
of combined radiotherapy (adjuvant and neoadjuvant) com-
pared with no radiotherapy.
Heterogeneity between studies51 was assessed in
Review Manager 5.3 using the Higgins and Thompson
I2 statistic52. Levels of heterogeneity were defined as:
low (I2 less than 50 per cent), moderate (I2 = 50–80 per
cent) and high (I2 above 80 per cent). A random-effects
model was used for cohorts with heterogeneity (I2 above
50 per cent)53. As heterogeneity was generally moderate
or high, and outcome measures differed between studies,
these were combined using the DerSimonian and Laird
random-effects model. Results of meta-analyses are shown
as forest plots. A sensitivity analysis was performed where
possible, to evaluate whether outcomes differed when
restricting the analysis exclusively to high-quality studies.
Clinically meaningful differences in QOL items/
questions or domain scores may vary depending on
response shift, that is a change in the meaning of QOL
scores over time54. This is relevant in longitudinal studies
and may influence clinical significance, defined as greater
than 5-point score differences for EORTC QLQ-C30
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Table 1 Study summaries: comparative adjuvant or neoadjuvant radiotherapy in autologous breast reconstruction, and
non-comparative studies (adjuvant radiotherapy or neoadjuvant radiotherapy only)
Reference Years Country
No. of
centres Type of BRR flap
Overall follow-up
(months)
Group differences
in baseline
characteristics¶ RT dose and regimen
Baumann
et al.69‡
2005–2009 USA 1 msTRAM; DIEP;
SIEA
11* n.a. Total 60Gy; missing
details
Billig
et al.62§
2012–2017 USA and
Canada
11 TRAM; DIEP; SIEA 24 Adjuvant RT: more
non-Hispanic patients
(P=0⋅001), bilateral
BRR (P=0⋅002),
DIEP/SIEA (P<0⋅001),
adjuvant
chemotherapy
(P<0⋅001); less TRAM
(P<0⋅001)#
Total 50⋅4Gy over
4weeks, daily (28
fractions of 1⋅8Gy)
Chatterjee
et al.59§
1995–2005 UK 1 DIEP 42 (12–120)† Adjuvant RT: more IDC
(P=0⋅02), LVI
(P=0⋅044), positive
axillary LN (P<0⋅001)
Total 45Gy over
4weeks (20
fractions)
Cooke
et al.60§
2012–2015 Canada 1 DIEP; SIEA 12 Adjuvant RT: higher TNM
staging, positive LN,
more chemotherapy (P
values not provided)
Total 50/50⋅4Gy over
4weeks, daily (25
fractions of 2Gy/28
fractions of 1⋅8Gy)
Huang
et al.63‡
1997–2001 Taiwan 1 TRAM 40 (24–74)† n.a. Total 50Gy; missing
details
Levine
et al.67‡
1999–2011 USA 1 msTRAM; DIEP;
SIEA
22⋅7* n.a. Missing details
Modarressi
et al.64‡
2007–2013 Switzerland 1 DIEP 1 n.a. Missing details
Mull et al.65‡ 2003–2014 USA 1 msTRAM;
TRAM; DIEP
1 Neoadjuvant RT: more
chemotherapy
(P<0⋅01), higher TNM
staging (P<0⋅01); less
hypertension/CAD
(P=0⋅03)
Missing details
O’Connell
et al.58‡
2009–2014 UK 1 DIEP 44⋅3 (i.q.r.
31⋅1–56⋅4)†
Adjuvant and
neoadjuvant RT: more
chemotherapy and
endocrine therapy as
less DCIS/less
advanced invasive
disease (P values not
provided)
Total 40Gy over
3weeks (15
fractions)
Peeters
et al.66‡
1997–2003 Belgium 2 DIEP ≥12 n.a. Total 50Gy; missing
details
Rogers and
Allen61‡
1994–1999 USA 1 DIEP 18⋅7* n.a. Total 50⋅5Gy over
6⋅5weeks (missing
details)
Temple
et al.68‡
1990–2001 USA 1 TRAM ≥12 n.a. Total 58Gy; missing
details
Values are *mean and †median (range), unless indicated otherwise. ‡Retrospective study; §prospective study. ¶Radiotherapy (RT) versus no RT, except
#group difference values are for adjuvant RT versus neoadjuvant RT. BRR, breast reconstruction; (ms)TRAM, (muscle-sparing) transverse rectus abdominis
myocutaneous; DIEP, deep inferior epigastric artery perforator; SIEA, superficial inferior epigastric artery perforator; IDC, invasive ductal carcinoma; LVI,
lymphovascular invasion; LN, lymph node; n.a., not applicable/available; CAD, coronary artery disease; DCIS, ductal carcinoma in situ.
and QLQ-BR2342,43,54. Clinically meaningful differences
are currently being evaluated using a number of methods
such as qualitative interviews and using predefined clinical
anchors55. Clinically meaningful differences in QOL
should be differentiated from statistical significance55.
BREAST-Q findings have been compared with large
population-derived normative data, facilitating clinically
meaningful interpretation of data56,57.
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Table 2 Surgical complications: immediate autologous breast reconstruction and adjuvant radiotherapy including non-comparative
studies (adjuvant radiotherapy only)
No. of patients Follow-up (months)
Total no. of
complications
No. of reoperations
for complications
Reference GRADE ROBINS-I
Adjuvant
RT
No adjuvant
RT
Adjuvant
RT
No adjuvant
RT
Adjuvant
RT
No adjuvant
RT
Adjuvant
RT
No adjuvant
RT
Chatterjee et al.59 Low Serious 22 46 54* 36* n.a. n.a. n.a. n.a.
Cooke et al.60 Moderate Moderate 64 61 12 12 20 16 6 1
O’Connell et al.58 Low Serious 28 80 27⋅5* 48⋅7* 11 20 4 8
Peeters et al.66 Low Serious 16 109 ≥12 ≥12 n.a. n.a. n.a. n.a.
Rogers and
Allen61
Low Serious 30 30 19⋅9 17⋅4 65 41 32 26
Billig et al.62 Moderate Moderate 108 n.a. 24 n.a. 81 n.a. 5 n.a.
Huang et al.63 Low Serious 82 n.a. 40* n.a. 131 n.a. 5 n.a.
*Values are median. GRADE, Grading of Recommendation, Assessment, Development, and Evaluation (tool for grading the quality of evidence);
ROBINS-I, Risk Of Bias In Non-randomised Studies – of Interventions (tool for assessing risk of bias); RT, radiotherapy; n.a., not applicable/available.
Table 3 Clavien–Dindo classification of surgical complications: immediate autologous breast reconstruction and adjuvant
radiotherapy including non-comparative studies (adjuvant radiotherapy only)
Adjuvant RT versus no adjuvant RT
Clavien-Dindo complication
grade†
Reference
Total flap
loss
Partial flap
loss* Fat necrosis*
Wound dehiscence
and delayed
wound healing* II IIIa IIIb
Chatterjee et al.59 n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Cooke et al.60 0 versus 0 9 versus 6 2 versus 1 3 versus 5 2 versus 4 n.a. 6 versus 1
O’Connell et al.58 0 versus 0 0 versus 0 1 versus 2 4 versus 9 3 versus 3 3 versus 3 1 versus 5
Peeters et al.66 n.a. n.a. 6 versus 36 n.a. n.a. n.a. n.a.
Rogers and
Allen61
n.a. n.a. 7 versus 0‡ 11 versus 8 5 versus 7 7 versus 0 25 versus 26
Billig et al.62 0 versus n.a. n.a. 4 versus n.a. 17 versus n.a. 8 versus n.a. n.a. 5 versus n.a.
Huang et al.63 0 versus n.a. n.a. 7 versus n.a. n.a. 82 versus
n.a.
5 versus n.a. n.a.
*Complication grades were not always defined or classified. †Grade II, complications requiring pharmacological treatment with drugs other than those
allowed for grade I complications (drugs other than antiemetics, antipyretics, analgesics, diuretics and electrolytes); grade IIIa, complications requiring
surgical intervention not under general anaesthesia; grade IIIb, complications requiring surgical intervention under general anaesthesia. RT, radiotherapy;
n.a. not applicable/available. ‡P< 0⋅050.
Results
A total of 697 studies were identified. Of these, 12
studies58–69 (including 1756 patients) evaluated adjuvant
radiotherapy (350 patients), neoadjuvant radiotherapy
(723) and no radiotherapy (683) (Fig. 1). There were
three prospective study designs59,60,62 and nine that
were retrospective58,61,63–69, but no RCTs. There were
two multicentre (1 prospective62 and 1 retrospective66)
and ten single-centre studies (2 prospective59,60 and
8 retrospective58,61,63–65,67–69) (Table 1). Study quality
(GRADE) was low in eight studies58,59,61,63–66,68 and mod-
erate in the other four60,62,67,69, with an overall high risk
of bias. A summary of baseline characteristics, including
numbers of centres, country of origin, dates, patient
numbers, breast cancer pathology and adjuvant medi-
cal treatments in comparative adjuvant and neoadjuvant
radiotherapy groups, including non-comparative studies,
is provided in Table S1 (supporting information).
Clinical outcomes (Tables 2–5)
No study prospectively graded surgical complications
according to an accepted classification such as CDC (fat
necrosis, partial or total flap loss, infection and wound
complications). One study64 graded partial flap loss using
a novel flap necrosis classification system, adapted from
Kwok et al.70. Only 30 per cent of all surgical complica-
tions (30 of 99) reported across the 12 included studies
were defined a priori.
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Table 4 Surgical complications: delayed autologous breast reconstruction and neoadjuvant radiotherapy including non-comparative
studies (neoadjuvant radiotherapy only)
No. of patients Follow-up (months)
Total no. of
complications
No. of reoperations
for complications
Reference GRADE ROBINS-I
Neoadjuvant
RT
No
neoadjuvant
RT
Neoadjuvant
RT
No
neoadjuvant
RT
Neoadjuvant
RT
No
neoadjuvant
RT
Neoadjuvant
RT
No
neoadjuvant
RT
Modarressi
et al.64
Low Serious 60 45 1 1 20 9 n.a. n.a.
Mull et al.65 Low Serious 142 312 1 1 26 45 26 45
O’Connell
et al.58
Low Serious 38 80 50⋅3* 48⋅7* 12 20 3 8
Peeters
et al.66
Low Serious 77 109 ≥12 ≥12 n.a. n.a. n.a. n.a.
Baumann
et al.69
Moderate Moderate 189 n.a. 11† n.a. 88 n.a. 69 n.a.
Billig
et al.62
Moderate Moderate 67 n.a. 24 n.a. 37 n.a. 1 n.a.
Levine
et al.67
Moderate Moderate 50 n.a. 22⋅7† n.a. n.a. n.a. 3 n.a.
Temple
et al.68
Low Serious 100 n.a. ≥12 n.a. 41 n.a. 18 n.a.
Values are *median and †mean.GRADE,Grading of Recommendation, Assessment, Development, andEvaluation (tool for grading the quality of evidence);
ROBINS-I, Risk Of Bias In Non-randomised Studies – of Interventions (tool for assessing risk of bias); RT, radiotherapy; n.a., not applicable/available.
Table 5 Clavien–Dindo classification of surgical complications: delayed autologous breast reconstruction and neoadjuvant
radiotherapy including non-comparative studies (neoadjuvant radiotherapy only)
Neoadjuvant RT versus no neoadjuvant RT
Clavien-Dindo complication grade†
Reference
Total
flap loss
Partial
flap loss* Fat necrosis*
Wound dehiscence
and delayed
wound healing* II IIIa IIIb
Modarressi et al.64 2 versus 1 12 versus 2 n.a. n.a. n.a. n.a. n.a.
Mull et al.65 5 versus 15 7 versus 5‡ n.a. n.a. n.a. n.a. 26 versus 45
O’Connell et al.58 0 versus 0 0 versus 0 2 versus 2 7 versus 9 2 versus 3 0 versus 3 3 versus 5
Peeters et al.66 n.a. n.a. 29 versus 36 n.a. n.a. n.a. n.a.
Baumann et al.69 5 versus n.a. 14 versus n.a. 15 versus n.a. 22 versus n.a. 4 versus n.a. n.a. 69 versus n.a.
Billig et al.62 0 versus n.a. n.a. 7 versus n.a. 11 versus n.a. 4 versus n.a. n.a. 1 versus n.a.
Levine et al.67 n.a. 1 versus n.a. n.a. n.a. n.a. n.a. n.a.
Temple et al.68 2 versus n.a. 7 versus n.a. 16 versus n.a. n.a. n.a. n.a. 18 versus n.a.
*Complication grades were not always defined or classified. †Grade II, complications requiring pharmacological treatment with drugs other than those
allowed for grade I complications (drugs other than antiemetics, antipyretics, analgesics, diuretics and electrolytes); grade IIIa, complications requiring
surgical intervention not under general anaesthesia; grade IIIb, complications requiring surgical intervention under general anaesthesia. RT, radiotherapy;
n.a. not applicable/available. ‡P< 0⋅050.
Adjuvant post-mastectomy radiotherapy
Meta-analyses comparing PMRT (350 patients; mean
follow-up 27⋅1 (range 12⋅0–54⋅0)months) and no
radiotherapy (326 patients; mean follow-up 25⋅2
(12⋅0–48⋅7)months) showed no interstudy differences
in rates of: overall complications (233 patients; odds
ratio (OR) 1⋅52 (95 per cent c.i. 0⋅84 to 2⋅75), Z= 1⋅40,
P= 0⋅160) (Fig. 2a); CDC grade III surgical complications
(233 patients; OR 2⋅35 (0⋅63 to 8⋅81), Z= 1⋅27, P= 0⋅200)
(Fig. 2b); CDC grade II (293 patients; OR 0⋅94 (0⋅32 to
2⋅76), Z= 0⋅11, P= 0⋅910) (Fig. 2c); or fat necrosis (418
patients; OR 1⋅83 (0⋅67 to 5⋅00), Z= 1⋅18, P= 0⋅240)
(Fig. 2d). There were no differences in rates of infection
(293 patients; OR 0⋅94 (0⋅32 to 2⋅76), Z= 0⋅11, P= 0⋅910)
(Fig. S1a, supporting information) or wound complications
(293 patients; OR 1⋅16 (0⋅56 to 2⋅39), Z= 0⋅40, P= 0⋅690)
(Fig. S1b, supporting information). There were no total
flap losses.
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Fig. 2 Forest plots comparing adjuvant radiotherapy with no radiotherapy
Cooke et al.60
Reference
a  Overall complications
RT No RT Odds ratioWeight (%) Odds ratio
O’Connell et al.58
20 of 64
11 of 28
31 of 92
16 of 61
20 of 80
36 of 141
57·9
42·1
100·0
1·28 (0·59, 2·78)
1·94 (0·78, 4·83)
1·52 (0·84, 2·75)
0·01 0·1
Favours RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·00; χ2= 0·47, 1 d.f., P = 0·49; I2= 0%
Test for overall effect: Z = 1·40, P = 0·16
Cooke et al.60
Reference
b  CDC grade III complications
RT No RT Odds ratioWeight (%) Odds ratio
O’Connell et al.58
6 of 64
4 of 28
10 of 92
1 of 61
8 of 80
9 of 141
31·6
68·4
100·0
6·21 (0·72, 53·15)
1·50 (0·41, 5·43)
2·35 (0·63, 8·81)
0·01 0·1
Favours RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·23; χ2= 1·29, 1 d.f., P = 0·26; I2= 22%
Test for overall effect: Z = 1·27, P = 0·20
Cooke et al.60
Reference
c  CDC grade II complications
RT No RT Odds ratioWeight (%) Odds ratio
O’Connell et al.58
2 of 64
3 of 28
10 of 122
4 of 61
3 of 80
14 of 171
28·0
29·8
100.0
0·46 (0·08, 2·61)
3·08 (0·58, 16·24)
Rogers and Allen 61 5 of 30 7 of 30 42·1 0·66 (0·18, 2·36)
0·94 (0·32, 2·76)
0·01 0·1
Favours RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·29; χ2= 2·92, 2 d.f., P = 0·23; I2= 31%
Test for overall effect: Z = 0·11, P = 0·91
Cooke et al.60
Reference
d  Fat necrosis
RT No RT Odds ratioWeight (%) Odds ratio
O’Connell et al.58
2 of 64
1 of 28
16 of 138
1 of 61
2 of 80
39 of 280
15·7
15·5
100·0
1·94 (0·17, 21·91)
1·44 (0·13, 16·57)
Peeters et al.66 6 of 16 36 of 109 57·7 1·22 (0·41, 3·61)
Rogers and Allen61 7 of 30 0 of 30 11·2 19·47 (1·06, 358·38)
1·83 (0·67, 5·00)
0·01 0·1
Favours RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·15; χ2= 3·40, 3 d.f., P = 0·33; I2= 12%
Test for overall effect: Z = 1·18, P = 0·24
aOverall complications, bClavien–Dindo classification (CDC) grade III complications, cCDC grade II complications, d fat necrosis. AMantel–Haenszel
random-effects model was used for meta-analysis. Odds ratios are shown with 95 per cent confidence intervals. RT, radiotherapy.
Neoadjuvant radiotherapy
Comparisons between neoadjuvant radiotherapy (723
patients; mean follow-up 16⋅8 (range 1⋅0–50⋅3)months)
and no radiotherapy (546 patients; mean follow-up 15⋅7
(1⋅0–48⋅7)months) showed no differences in overall
complications (677 patients; OR 1⋅45 (95 per cent c.i.
0⋅97 to 2⋅18), Z= 1⋅82, P= 0⋅070) (Fig. 3a) and CDC
grade III surgical complications (572 patients; OR
1⋅24 (0⋅76 to 2⋅04), Z= 0⋅85, P= 0⋅390) (Fig. 3b). One
comparative study58 reported similar CDC grade II
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Fig. 3 Forest plot comparing neoadjuvant radiotherapy with no radiotherapy
Modarressi et al.64
Reference
a  Overall complications
Neoadjuvant RT No RT Odds ratioWeight (%) Odds ratio
Mull et al.65
20 of 60
26 of 142
58 of 240
9 of 45
45 of 312
74 of 437
19·8
57·8
100·0
2·00 (0·81, 4·95)
1·33 (0·78, 2·26)
O’Connell et al.58 12 of 38 20 of 80 22·4 1·38 (0·59, 3·24)
1·45 (0·97, 2·18)
0·01 0·1
Favours neoadjuvant RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·00; χ2= 0·60, 2 d.f., P = 0·74; I2= 0%
Test for overall effect: Z = 1·82, P = 0·07
Mull et al.65
Reference
b  CDC grade III complications
Neoadjuvant RT No RT Odds ratioWeight (%) Odds ratio
O’Connell et al.58
26 of 142
3 of 38
29 of 180
45 of 312
8 of 80
53 of 392
87·3
12·7
100·0
1·33 (0·78, 2·26)
0·77 (0·19, 3·09)
1·24 (0·76, 2·04)
0·01 0·1
Favours neoadjuvant RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·00; χ2= 0·52, 1 d.f., P = 0·47; I2= 0%
Test for overall effect: Z = 0·85, P = 0·39
O’Connell et al.58
Reference
c  Fat necrosis
Neoadjuvant RT No RT Odds ratioWeight (%) Odds ratio
Peeters et al.66
2 of 38
29 of 77
31 of 115
2 of 80
36 of 109
38 of 189
8·5
91·5
100·0
2·17 (0·29, 16·00)
1·23 (0·67, 2·25)
1·29 (0·72, 2·30)
0·01 0·1
Favours neoadjuvant RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·00; χ2= 0·29, 1 d.f., P = 0·59; I2= 0%
Test for overall effect: Z = 0·85, P = 0·40
aOverall complications, bClavien–Dindo classification (CDC) grade III complications, c fat necrosis. AMantel–Haenszel random-effects model was used
for meta-analysis. Odds ratios are shown with 95 per cent confidence intervals. RT, radiotherapy.
complications between neoadjuvant and no radiotherapy
(118 patients; OR 1⋅43 (0⋅23 to 8⋅91), Z= 0⋅38, P= 0⋅700).
There were no differences in rates of fat necrosis (304
patients; OR 1⋅29 (0⋅72 to 2⋅30), Z= 0⋅85, P= 0⋅400)
(Fig. 3c). Rates of partial flap loss were higher for neoad-
juvant radiotherapy than for no radiotherapy (559
patients; OR 3⋅85 (1⋅51 to 9⋅76), Z= 2⋅83, P= 0⋅005)
(Fig. S2a, supporting information), with no differ-
ences in rates of total flap loss (559 patients; OR 0⋅81
(0⋅31 to 2⋅09), Z= 0⋅44, P= 0⋅660) (Fig. S2b, supporting
information).
Combined adjuvant and neoadjuvant radiotherapy
Meta-analyses of pooled PMRT and neoadjuvant radio-
therapy compared with pooled no radiotherapy groups
(mean follow-up 18⋅3 (range 1⋅0–48⋅7) months) were
performed as a potential hypothesis-generating exercise.
This showed significantly higher overall complications
in the combined radiotherapy groups compared with
no radiotherapy (830 patients; OR 1⋅46 (95 per cent c.i.
1⋅04 to 2⋅07), Z= 2⋅16, P= 0⋅030) (Fig. 4a). There were
no interstudy differences in: CDC grade III complica-
tions (725 patients; OR 1⋅38 (0⋅83 to 2⋅32), Z= 1⋅24,
P= 0⋅220) (Fig. 4b); CDC grade II complications (331
patients; OR 0⋅89 (0⋅37 to 2⋅10), Z= 0⋅28, P= 0⋅780)
(Fig. S3a, supporting information); rates of fat necro-
sis (533 patients; OR 1⋅59 (0⋅96 to 2⋅64), Z= 1⋅79,
P= 0⋅070) (Fig. 4c); or emergency reoperations for com-
plications (725 patients; OR 1⋅38 (0⋅83 to 2⋅32), Z= 1⋅24,
P= 0⋅220) (Fig. S3b, supporting information). Rates
of partial flap loss were also higher in the combined
versus no radiotherapy groups (684 patients; OR 2⋅59
(1⋅27 to 5⋅28), Z= 2⋅63, P= 0⋅009) (Fig. S3c, supporting
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Fig. 4 Forest plot comparing combined adjuvant and neoadjuvant radiotherapy with no radiotherapy
Modarressi et al.64
Reference
a  Overall complications
RT No RT Odds ratioWeight (%) Odds ratio
Mull et al.65
20 of 60
26 of 142
89 of 332
9 of 45
45 of 312
90 of 498
14·5
42·5
100·0
2·00 (0·81, 4·95)
Cooke et al.60 20 of 64 16 of 61 19·7 1·28 (0·59, 2·78)
1·33 (0·78, 2·26)
O’Connell et al.58 23 of 66 20 of 80 23·3 1·60 (0·78, 3·28)
1·46 (1·04, 2·07)
0·01 0·1
Favours RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·00; χ2= 0·76, 3 d.f., P = 0·86; I2= 0%
Test for overall effect: Z = 2·16, P = 0·03
Mull et al.65
Reference
b  CDC grade III complications
RT No RT Odds ratioWeight (%) Odds ratio
O’Connell et al.58
26 of 142
7 of 66
39 of 272
45 of 312
8 of 80
54 of 453
72·8
21·5
100·0
1·33 (0·78, 2·26)
Cooke et al.60 6 of 64 1 of 61 5·6 6·21 (0·72, 53·15)
1·07 (0·37, 3·12)
1·38 (0·83, 2·32)
0·01 0·1
Favours RT Favours no RT
1 10 100
Total
Heterogeneity: τ2= 0·02; χ2= 2·15, 2 d.f., P = 0·34; I2= 7%
Test for overall effect: Z = 1·24, P = 0·22
O’Connell et al.58
Reference
c  Fat necrosis
RT No RT Odds ratioWeight (%) Odds ratio
Peeters et al.66
3 of 66
35 of 93
47 of 253
2 of 80
36 of 109
39 of 280
7·3
87·0
100·0
1·86 (0·30, 11·46)
Cooke et al.60 2 of 64 1 of 61 4·2 1·94 (0·17, 21·91)
1·22 (0·69, 2·18)
Rogers and Allen61 7 of 30 0 of 30 1·6 19·47 (1·06, 358·38)
1·59 (0·96, 2·64)
0·01 0·1
Favours RT Favours no RT
1 10 100
Total
Heterogeneity: χ2= 3·68, 3 d.f., P = 0·30; I2= 18%
Test for overall effect: Z = 1·79, P = 0·07
aOverall complications, bClavien–Dindo classification (CDC) grade III complications, c fat necrosis. AMantel–Haenszel random-effects model was used
for meta-analysis. Odds ratios are shown with 95 per cent confidence intervals. RT, radiotherapy.
information), with no differences in rates of total flap
loss (559 patients; OR 0⋅81 (0⋅31 to 2⋅09), Z= 0⋅44,
P= 0⋅660) (Fig. S3d, supporting information), infec-
tion (331 patients; OR 0⋅89 (0⋅37 to 2⋅10), Z= 0⋅28,
P= 0⋅780) (Fig. S3e, supporting information) or wound
complications (dehiscence/delayed wound healing) (331
patients; OR 1⋅29 (0⋅68 to 2⋅47), Z= 0⋅78, P= 0⋅430)
(Fig. S3f , supporting 1information).
Assessment of heterogeneity and meta-analyses
Clinical outcomes within studies of PMRT versus no
radiotherapy were homogeneous (I2 values below 50 per
cent). All remaining meta-analyses of outcomes were
similar (neoadjuvant radiotherapy versus no radiotherapy,
pooled PMRT and neoadjuvant radiotherapy versus no
radiotherapy).
Quality of life
There was limited reporting of patient-reported QOL;
outcomes were detailed in only two prospective studies60,62
and one retrospective study58, with small patient numbers
and short follow-ups for the PMRT groups58,60,62. A priori
hypothesis-driven selection of QOL domains was absent
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from methods58,60,62, with no reporting of missing data or
how this problem was tackled34.
Three studies58,60,62 used the BREAST-Q and one60
used the breast cancer-specific questionnaire (EORTC
QLQ-BR23)42. One small study58 reported significantly
better ‘satisfaction with breast’ (P= 0⋅008) after a median
follow-up of 27⋅5months for PMRT compared with
48⋅7months for no radiotherapy (Table S2, supporting
information). The moderate-quality comparative prospec-
tive study60 found a significant adverse impact of PMRT
on breast symptoms at 1 year (P< 0⋅001) compared with
no radiotherapy (Table S2, supporting information).
The third study62 evaluated serial QOL outcomes, con-
cluding a significant impact of PMRT on QOL domains
(BREAST-Q) at 1 and 2 years, despite the absence of a
control group (no radiotherapy). Moreover, clinical signif-
icance was defined as P= 0⋅05, which may not account for
multiple variables (Table S2, supporting information)43,62.
Highly significant abdominal adverse effects in a small
patient group (108 patients) may be unrelated to PMRT,
but rather an indication of donor site morbidity. Interest-
ingly, when evaluating the impact of neoadjuvant radio-
therapy in a small non-comparative study62, significant
time-related improvements in most QOL domains were
observed, except lower physical well-being relating to the
abdomen at 1 year (Table S3, supporting information).
Cosmetic outcomes
Three studies58,61,63 evaluated PMRT and the effects on
aesthetic outcomes (187 patients). There was no stan-
dardized evaluation of cosmetic outcomes, precluding
meta-analyses. Studies lacked robust methodology.
Discussion
The mixture of underpowered observational studies
included in this review were, in large part, lacking con-
temporaneous data to reflect current practice. Most were
retrospective single-centre cohorts, demonstrating poor
levels of clinical evidence (levels 3 and 4) with insufficient
follow-up11.
A previous study24 of over 40 000 women undergoing
BRR in 134 studies found that only 20 per cent reported
a priori surgical complications, as well as inconsistent
interstudy definitions24. The present review found sim-
ilar interstudy discrepancies, without uniform adoption
of the CDC26. The present authors graded all reported
surgical complications using the CDC. All surgical inter-
ventions were graded as CDC IIIa or IIIb, and surgi-
cal reoperations were differentiated according to whether
they were for complications or cosmetic revisions. Some
complications were not amenable to retrospective grading
in three studies64,66,67. In one66, it was not possible to deter-
mine whether fat necrosis required surgical revision for
each radiotherapy group (adjuvant or neoadjuvant), com-
pared with no radiotherapy. A second64 omitted individual
abdominal complications relative to timings of radiother-
apy, and the third67 omitted overall numbers of complica-
tions. Reviewed studies also failed to define postoperative
wound infections according to Centers for Disease Control
and Prevention criteria71.
The IDEAL (Idea, Development, Exploration, Assess-
ment, Long-term study) Collaboration describes key
methodological criteria for robust prospective cohort
studies72: studies should be powered on the effect size
of primary outcomes evaluating interventions of interest.
The Mastectomy and Breast Reconstruction Outcomes
Collaborative (MROC) is a multicentre prospective cohort
study that provides IDEAL level 2b evidence for clinical
safety and satisfactory QOL outcomes in the evaluation
of surgical complications in immediate autologous recon-
structions with PMRT versus no radiotherapy (delayed
BRR) in 11 US centres17,60. The MROC cohort data were
excluded from this systematic review based on its reporting
of group-related summative data for all types of autologous
reconstruction, as opposed to individual abdominal donor
sites.
The MROC has reported all surgical complications at
2 years and demonstrated that PMRT (versus no radiother-
apy) was significantly associated with a greater risk of devel-
oping any complication (OR 1⋅50 (95 per cent c.i. 1⋅20
to 1⋅86); P< 0⋅001), reoperative complications (OR 1⋅52
(1⋅17 to 1⋅97); P< 0⋅002) and wound infection (OR 2⋅77
(1⋅78 to 4⋅31); P< 0⋅001)16. Autologous BRR was done
more commonly in irradiated than non-irradiated patients
(38 versus 25 per cent respectively; P< 0⋅001), with simi-
larly low rates (1–2⋅4 per cent) of reconstruction failure at
2 years17.
Eligible studies in the present systematic review were sig-
nificantly underpowered in comparison with the MROC
study, which evaluated irradiated autologous BRR at 1 year
(236 patients) and 2 years (199), and non-irradiated pro-
cedures at 1 year (1625) and 2 years (332). The MROC
data showed no differences between radiotherapy and no
radiotherapy groups in the rates of total complications
(25⋅6 versus 28⋅3 per cent respectively), major compli-
cations (17⋅6 versus 22⋅9 per cent) or flap failure (1⋅0
versus 2⋅4 per cent) at 2 years after immediate autologous
reconstruction17. Studies in the present review showed
significantly lower rates of major complications after
radiotherapy comparedwith theMROC results, suggesting
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suboptimal overall reporting of surgical complications in
the reviewed studies24.
The retrospective grading of surgical complications in
the two moderate-quality studies reported showed a rate
of major complications (CDC grade IIIb) of 9 per cent
(6 of 64) at 1 year, and 4⋅6 per cent (5 of 108) at 2 years60,62.
These rates are also likely to reflect under-reporting com-
pared with the MROC rates of 14⋅8 per cent (35 of 236)
at 1 year and 17⋅6 per cent (35 of 199) at 2 years17. Despite
its strengths, the MROC cohort is based on the review of
complications from electronic patient records, potentially
also underestimating true complication rates17.
One way to measure what matters to patients is to use
patient-reported outcome measures (PROMs) to assess the
effects of disease or treatment on symptoms, function-
ing and health-related QOL34. In this systematic review,
PROMs were poorly reported and underpowered for over-
all small effect sizes of individual QOL domains43. Pre-
liminary conclusions regarding statistical significance were
not substantiated by adequate patient numbers, lack of
a comparator group or prospectively defined time points
for questionnaire collection58. Standardized and objective
evaluations of cosmetic outcome have also remained elu-
sive with emerging adoption of newer technologies such
as the Vectra® XT58. Robust study designs evaluating
these innovations should be accompanied by surgery- and
disease-specific questionnaires34.
Clear recommendations for the optimal timing of radio-
therapy in relation to autologous BRR will remain elu-
sive until information from high-quality systematic reviews
forms part of shared preoperative decision-making73.
Adequately powered prospective studies and ongoing
audits, to allow comparisons of postoperative radiotherapy
with neoadjuvant radiotherapy, are warranted. Current evi-
dence for irradiating autologous abdominal flaps remains
weak, involving only two moderate-quality studies of the
12 included in this report. Future cohort studies should be
designed and powered to take advantage of newly evolv-
ing study designs, such as multiple-cohort RCTs or trials
within cohorts74. These designs permit collection of big
data within registry or cohort platforms, and allow mul-
tiple synchronous randomized trials to be conducted in a
cost-effective manner74.
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